54.87
0.49 (0.90%)
| Previous Close | 54.38 |
| Open | 54.83 |
| Volume | 1,946,902 |
| Avg. Volume (3M) | 2,808,193 |
| Market Cap | 10,350,566,400 |
| Price / Earnings (Forward) | 2.50 |
| Price / Sales | 3.43 |
| Price / Book | 4.12 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -36.06% |
| Operating Margin (TTM) | -11.53% |
| Diluted EPS (TTM) | -5.53 |
| Quarterly Revenue Growth (YOY) | 10.90% |
| Total Debt/Equity (MRQ) | 105.93% |
| Current Ratio (MRQ) | 2.73 |
| Operating Cash Flow (TTM) | 323.66 M |
| Levered Free Cash Flow (TTM) | 163.08 M |
| Return on Assets (TTM) | -1.83% |
| Return on Equity (TTM) | -36.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Exact Sciences Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -2.5 |
| Average | -2.50 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.92% |
| % Held by Institutions | 105.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 72.00 (Baird, 31.22%) | Buy |
| Median | 62.50 (13.91%) | |
| Low | 54.00 (RBC Capital, -1.59%) | Hold |
| Average | 62.83 (14.51%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 49.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 24 Jun 2025 | 65.00 (18.46%) | Buy | 52.34 |
| 02 May 2025 | 75.00 (36.69%) | Buy | 51.55 | |
| Baird | 02 May 2025 | 72.00 (31.22%) | Buy | 51.55 |
| Evercore ISI Group | 02 May 2025 | 66.00 (20.28%) | Buy | 51.55 |
| RBC Capital | 02 May 2025 | 54.00 (-1.59%) | Hold | 51.55 |
| Guggenheim | 11 Apr 2025 | 60.00 (9.35%) | Buy | 44.45 |
| Mizuho | 10 Apr 2025 | 60.00 (9.35%) | Buy | 43.74 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |